New oral combo aims to boost melanoma treatment power
NCT ID NCT05089370
Summary
This study is testing whether adding an oral drug called DEC-C to standard immunotherapy (nivolumab) can make treatment more effective for people with advanced mucosal melanoma. The goal is to see if this combination can better activate the immune system against the cancer. The trial will first determine a safe dose and then check if the combination helps shrink tumors or slow disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.